

Influenza Antiviral Drugs Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
The Influenza Antiviral Drugs market is experiencing steady growth, driven by increasing influenza incidence and rising medication demand. The market size was valued at approximately $XX billion in 2023, with projected growth due to advancements in drug development and expanding healthcare access. Competitive dynamics emphasize innovation and strategic partnerships.
◍ GSK
◍ Boehringer Ingelheim
◍ Merck
◍ Novartis
◍ Beximco Pharmaceuticals
◍ Pfizer
◍ Roche
◍ Johnson & Johnson
◍ Sanofi
◍ Cipla Limited
◍ Natco Pharma
◍ Seqirus
◍ Adamas Pharmaceuticals, Inc.
◍ Teva Pharmaceuticals
◍ Daiichi Sankyo Company
The Influenza Antiviral Drugs Market features competitors like GSK, Boehringer Ingelheim, Merck, and Roche, focusing on innovative therapies and global distribution. Companies enhance market growth through R&D, strategic partnerships, and expanding product portfolios, driving sales. Actual sales figures include:
- Merck: $2.2 billion (2022)
- Pfizer: $5.8 billion (2023) Request Sample Report
◍ Clinics
◍ Ambulatory Surgical Centers
◍ Pharmacies
Others ◍ Hospitals
◍ Oseltamivir
Zanamivir
Peramivir
Adamantanes
◍ Others
Request Sample Report
Request Sample Report
$ 16.31 Billion